DSpace コレクション: 1993-031993-03http://hdl.handle.net/2433/1163712024-03-29T08:42:10Z2024-03-29T08:42:10ZEndopyelotomyの臨床経験植原, 秀和渡辺, 泱斉藤, 雅人内田, 睦今出, 陽一朗伊藤, 吉三中村, 雅至邵, 仁哲http://hdl.handle.net/2433/1178082021-09-15T09:53:50Z1993-03-01T00:00:00Zタイトル: Endopyelotomyの臨床経験
著者: 植原, 秀和; 渡辺, 泱; 斉藤, 雅人; 内田, 睦; 今出, 陽一朗; 伊藤, 吉三; 中村, 雅至; 邵, 仁哲
抄録: 腎盂尿管移行部狭窄症13腎に対して施行したendopyelotomyの結果ついて検討した結果, 先天性腎盂尿管移行部狭窄症に対する成功率は高かったが, 2次性腎盂尿管移行部狭窄症に対する成功率が, 諸家の報告に比べて低かった。この原因として狭窄部尿管の状態が悪い症例が多かったことが考えられた; From July 1986, percutaneous endopyelotomy was performed on a total of 12 patients (13 kidneys) including 8 males and 4 females with ureteropelvic junction (UPJ) obstruction. Of the 13 kidneys, 9 had primary UPJ obstruction and 4 had secondary UPJ obstruction. A rigid urethrotome (cold knife) was employed in 12 cases and a flexible electorotome (hot knife) in one case. A stent ureteral catheter was placed for 3 to 31 weeks after the procedure. The outcome was evaluated by radiography and urodynamic examinations. A successful outcome was obtained in 8 of 9 kidneys with primary UPJ obstruction and in 1 of 4 kidneys with secondary UPJ obstruction. These findings suggest that percutaneous endopyelotomy is useful in the treatment of primary UPJ obstruction.1993-03-01T00:00:00Z尿路移行上皮癌に対するMethotrexate,Etoposide,Cisplatinum併用療法でのRecombinant human granulocyte colony stimulating factorの臨床効果三浦, 猛村井, 哲夫志村, 英俊近藤, 猪一郎http://hdl.handle.net/2433/1178072021-09-15T09:53:50Z1993-03-01T00:00:00Zタイトル: 尿路移行上皮癌に対するMethotrexate,Etoposide,Cisplatinum併用療法でのRecombinant human granulocyte colony stimulating factorの臨床効果
著者: 三浦, 猛; 村井, 哲夫; 志村, 英俊; 近藤, 猪一郎
抄録: 尿路移行上皮癌患者に於いてメトトレキセート, エトポシド及びシスプラチン(MEC)療法後, 組換人顆粒球コロニー形成刺激因子(rhG-CSF)を投与した。rhG-CSF 2μg/kgの皮下注射は, 白血球数が3000/mm3以下に減少した後(短期投与), 或いはMEC療法終了直後(予防的投与), にそれぞれ開始した。好中球数の最低値は, rhG-CSF非投与の対照群, 短期投与群, 及び予防的投与群でそれぞれ275±77, 250±317, 及び2066±47/mm3であった。好中球数が1000/mm3未満の日数は, 対照群, 短期投与群, 及び予防的投与群でそれぞれ6.6±0.6, 4±2, 及び0.9±0.5日であった。対照群と予防的投与群との間の差異は推計学的に有意であった; We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy. Recombinant human G-CSF was administered at 2 micrograms/kg subcutaneously starting after the white blood cell count was less than 3, 000/mm3 (short administration) or starting immediately after finishing MEC therapy (prophylactic administration). The median white blood cell nadir for the control group, short administration group and prophylactic administration group, was 275 +/- 77, 250 +/- 317 and 2, 066 +/- 47/mm3, respectively. The number of days with a white blood count of less than 1, 000/mm3 for the control group, short administration group and prophylactic administration group was 6.6 +/- 0.6, 4 +/- 2 and 0.9 +/- 0.5 days, respectively. The difference between the control group and prophylactic administration group was statistically significant (p < 0.01). These findings indicated that the prophylactic administration of rhG-CSF following MEC therapy was effective for preventing leukopenia. Other side effects of stomatitis, diarrhea and pneumonia were also decreased using rhG-CSF after MEC therapy.1993-03-01T00:00:00Zヒト前立腺組織特異抗原の研究 : 未知の抗原に対するモノクローナル抗体作製法のモデル吉貴, 達寛岡田, 裕作友吉, 唯夫上田, 正道小川, 修吉田, 修http://hdl.handle.net/2433/1178062021-09-15T09:53:50Z1993-03-01T00:00:00Zタイトル: ヒト前立腺組織特異抗原の研究 : 未知の抗原に対するモノクローナル抗体作製法のモデル
著者: 吉貴, 達寛; 岡田, 裕作; 友吉, 唯夫; 上田, 正道; 小川, 修; 吉田, 修
抄録: 前立腺分泌細胞, 基底細胞, 間質細胞などの混合物を免疫原にし, BPH切片に対する蛍光抗体法でスクリーニングしてマウスモノクローナル抗体を作製した。前立腺分泌細胞に良く反応し, ホルマリン固定パラフィン切片にも適用可能である, PAP, PSAにそれぞれ特異的な抗体を産生する細胞を1クローンずつ樹立できた; Mouse monoclonal antibodies were prepared using a cell mixture containing prostatic secretory, basal cells and stromal cells as an immunogen, and by the immunofluorescence method with cryosections of prostate tissue. An immunohistochemical screening process was used in the expectation that it would help identify not only the antibodies reacting with the secretory cells predominant in the prostate but also those reacting with relatively rare cells in the prostate tissue. Two cell clones have been established which produce antibodies (IgG1) that react well with prostatic secretory cells: a clone producing antibodies specific to prostatic acid phosphatase (PAP) and one producing antibodies specific to prostate-specific antigen (PSA). These antibodies could recognize the native antigens in the seminal plasma, respectively. These findings indicate that antibodies recognizing only one substance can be prepared, even when a mixture of prostatic tissue including many proteases is used as an immunogen. Production of antibodies against prostate-specific antigens other than PAP and PSA by this method should provide a useful means for analyzing unknown antigens in the prostate.1993-03-01T00:00:00Z前立腺集団検診における血中前立腺特異抗原(PSA)値の検討加藤, 幹雄岡田, 耕市http://hdl.handle.net/2433/1178052021-09-15T09:53:50Z1993-03-01T00:00:00Zタイトル: 前立腺集団検診における血中前立腺特異抗原(PSA)値の検討
著者: 加藤, 幹雄; 岡田, 耕市
抄録: 集団検診受診の55歳以上の男子647例で直腸診, 経直腸的超音波断層法, 及び血清PSA(前立腺特異抗原)測定を行った。前立腺癌7例及び要治療前立腺肥大症53例を発見した。癌患者中6例でPSA値は3.6ng/ml以上, 1例で2.6ng/mlであった。前立腺癌及び良性前立腺肥大症の臨床的徴候がない587例中564例でPSA値は2.6ng/ml以下であった。前立腺疾患がなく, PSA値が2.6ng/ml以上を示す症例の比率は全症例3.4%に過ぎなかった; While it is widely recognized that elevated prostate specific antigen (PSA) correlates with the presence of prostate cancer, little data exist on the use of PSA as the initial test in the mass screening for prostate diseases. Thus, digital rectal examination, transrectal ultrasonography of the prostate as well as measurements of serum PSA were performed in a series of 647 men 55 years old or older who participated in the mass screening. We found 7 patients with prostatic cancer (1.1%) and 53 with benign prostatic hypertrophy faced with the necessity of the therapy (8.2%). The PSA values of 6 cancer patients exceeded 3.6 ng/ml and that of one cancer patient was 2.6 ng/ml. While 587 subjects were judged to be without clinical evidence of prostate cancer and benign prostatic hypertrophy, 564 of them has PSA values under 2.6 ng/ml. The proportion of those who were free from prostatic diseases and had a PSA value of 2.6 ng/ml or more was only 3.4% of all participants. Since the proportion of the subjects falsely screened at a relatively lower cut-off point of PSA was quite low, the measurement of serum PSA is suggested to be useful as the initial test in the mass screening for prostatic diseases.1993-03-01T00:00:00Z